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Long-term effectiveness of oral second-generation antipsychotics in 
patients with schizophrenia and related disorders: a systematic review 
and meta-analysis of direct head-to-head comparisons
Taishiro Kishimoto1-4, Katsuhiko Hagi2,5, Masahiro Nitta5, John M. Kane2-4, Christoph U. Correll2-4,6
1Keio University School of Medicine, Tokyo, Japan; 2Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, NY, USA; 3Donald and Barbara 
Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, NY, USA; 4Feinstein Institute for Medical Research, Manhasset, New York, NY, USA; 5Sumitomo 
Dainippon Pharma Co., Ltd., Tokyo, Japan; 6Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany
Second-generation antipsychotics (SGAs) are recommended for maintenance treatment in schizophrenia. However, comparative long-term ef-
fectiveness among SGAs is unclear. Here we provide a systematic review and meta-analysis of randomized trials lasting ≥6 months comparing 
SGAs head-to-head in schizophrenia and related disorders. The primary outcome was all-cause discontinuation. Secondary outcomes included 
efficacy and tolerability, i.e., psychopathology, inefficacy-related and intolerability-related discontinuation, relapse, hospitalization, remission, 
functioning, quality of life, and adverse events. Pooled risk ratio and standardized mean difference were calculated using random-effects models. 
Across 59 studies (N=45,787), lasting 47.4±32.1 weeks (range 24-186), no consistent superiority of any SGA emerged across efficacy and tolerability 
outcomes. Regarding all-cause discontinuation, clozapine, olanzapine and risperidone were significantly (p<0.05) superior to several other SGAs, 
while quetiapine was inferior to several other SGAs. As to psychopathology, clozapine and olanzapine were superior to several other SGAs, while 
quetiapine and ziprasidone were inferior to several other SGAs. Data for other efficacy outcomes were sparse. Regarding intolerability-related 
discontinuation, risperidone was superior and clozapine was inferior to several other SGAs. Concerning weight gain, olanzapine was worse than 
all other compared non-clozapine SGAs, and risperidone was significantly worse than several other SGAs. As to prolactin increase, risperidone 
and amisulpride were significantly worse than several other SGAs. Regarding parkinsonism, olanzapine was superior to risperidone, without 
significant differences pertaining to akathisia. Concerning sedation and somnolence, clozapine and quetiapine were significantly worse than 
some other SGAs. In summary, different long-term SGA efficacy and tolerability patterns emerged. The long-term risk-benefit profiles of specific 
SGAs need to be tailored to individual patients to optimize maintenance treatment outcomes.
Key words: Second-generation antipsychotics, maintenance treatment, randomized controlled trials, treatment discontinuation, efficacy, 
tolerability, clozapine, olanzapine, risperidone
(World Psychiatry 2019;18:208–224)
Schizophrenia is a mental disorder whose course is general-
ly characterized by repeated relapses as well as a worsening of 
psychopathology and social functioning, thus requiring main-
tenance treatment1-3. Antipsychotics are efficacious for relapse 
prevention in chronic and first-episode patients4,5, reducing 
relapse risk by 2-6-fold versus no antipsychotic treatment2,4-6.
A previous meta-analysis by our group, comparing second- 
generation antipsychotics (SGAs) with first-generation antipsy-
chotics (FGAs), found that the former as a class were superior 
to the latter regarding relapse prevention, all-cause discontinu-
ation and other relapse-related outcomes3.
Despite the importance of long-term treatment in schizo-
phrenia, in which the magnitude of benefits and risks of medi -
cations may be different from acute phase treatment, no com-
prehensive meta-analysis of the comparative long-term effec-
tiveness, efficacy and safety among oral SGAs currently exists7.
Although one meta-analysis targeted maintenance trials that 
compared antipsychotics with placebo2, indirect comparisons 
using placebo as the common comparator are not conclusive8. 
Further, a multiple treatment meta-analysis, which includes 
indirect comparisons, is not necessarily ideal, especially when 
the number of trials comparing antipsychotics directly is lim-
ited and when homogeneity of these trials cannot be assured9.
Knowledge about the comparative effectiveness, efficacy and 
tolerability of SGAs in the long-term treatment of schizophre-
nia is important7. Specifically, differences in side effect risk9-11, 
some of which may increase with time, need to be weighed 
against potential differences in long-term effectiveness and 
 efficacy.
Here we report the results of the first comprehensive meta- 
analysis of head-to-head randomized controlled trials compar-
ing two or more SGAs in the long-term treatment of schizophre-
nia, aiming to assess the comparative effectiveness, efficacy and 
safety of these medications.
METHODS
The meta-analysis was performed following PRISMA guide-
lines12.
Search and inclusion criteria
We conducted an electronic search without language restric-
tions using MEDLINE/PubMed, the Cochrane library, ISI Web 
of Science, PsycINFO, CINAHL and the US National Institutes 
of Health clinical trials registry (http://www.clinicaltrials.gov). 
The following search terms were used: antipsychotic(s); neu-
roleptic(s); individual names of SGAs; schizophrenia; random, 
randomly, randomized; and maintenance, relapse, discontin-
uation or long-term. The last search was done on  October 29, 
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2018. The electronic search was supplemented by a hand 
search of reference lists of relevant studies and reviews. Au-
thors and companies were contacted to provide missing infor-
mation and un published data.
We included randomized, head-to-head comparisons of oral 
SGAs in adults with schizophrenia or schizoaffective disorder 
which reported on treatment discontinuation, whether ran-
domization occurred during the acute or maintenance phase. As 
we aimed to focus on the comparative long-term effectiveness of 
SGAs, we only included head-to-head studies lasting ≥6 months.
We excluded studies with >20% of non- schizophrenia/schizo-
affective disorder patients. As long-acting injectable formula-
tion enhances the adherence and therefore has a significant 
impact on long-term outcome13,14, we excluded studies on long-
acting antipsychotics.
The search, selection of the literature, and data extraction were 
conducted independently by ≥2 reviewers (KH, MN, TK, CC). 
Disagreements were resolved by consensus.
Outcomes
The primary outcome was all-cause discontinuation at study 
endpoint.
Secondary outcomes included: a) psychopathology score 
change, measured by the Positive and Negative Syndrome Scale 
(PANSS), the Brief Psychiatric Rating Scale (BPRS) or the Clini-
cal Global Impression - Severity (CGI-S) score (mixed models or 
last-observation-carried-forward was prioritized over observed 
cases analysis); b) inefficacy-related discontinuation (as report-
ed by the original study authors); c) intolerability- related discon-
tinuation (as reported by the original study authors); d) relapse 
(as reported by the original study authors); e) hospitalization; f) 
remission (as reported by the original study authors); g) func-
tioning score; h) quality of life (QOL); and i) adverse events.
Adverse events included: weight gain (as change from base-
line or proportion of patients with clinically significant increase); 
prolactin increase (as change from baseline or proportion of pa-
tients with hyperprolactinemia); neuromotor adverse effects, 
including parkinsonism assessed with the Simpson-Angus Rat-
ing Scale or use of anticholinergics, akathisia and dyskinesia; 
and sedation and/or somnolence.
Data analysis
SGAs were compared individually for each outcome. We 
applied a “once-randomized-analyzed” intent-to-treat (ITT) 
endpoint analysis. In studies that followed patients even after 
they were switched off the originally allocated medication dur-
ing the study period, we analyzed the primary outcome based 
only on the first medication but, for secondary outcomes, we 
extracted and analyzed the data as reported in the ITT sample.
Pooled risk ratio (RR) and standardized mean difference 
(SMD) with 95% confidence intervals (CIs) were calculated  using 
random-effects models15. RR values <1 indicate superiority of 
the first SGA for negative outcomes (such as all-cause discon-
tinuation, relapse, inefficacy-related and intolerability- related 
discontinuation), while RR values >1 indicate superiority for the 
only positive outcome, remission. For simplicity we adjusted ef-
fect sizes, so that SMDs <0 indicate superiority of the first SGA, 
independent of whether a lower value (e.g., psychopathology) or 
higher value (e.g., functioning, QOL) is a positive outcome.
Number-needed-to-treat (NNT) was calculated when cat-
egorical outcome differences were significant. Heterogeneity 
was only inspected when ≥2 studies were analyzed, using the 
chi-square test (p<0.1 indicating significant heterogeneity)16 
and the I2 statistic (I2≥50% indicating significant heterogene-
ity)17. For study quality assessment, we used the Jadad scale18, 
that provides a sum score for sensitivity analyses.
In addition, a priori-defined subgroup analyses of the 
 primary outcome were conducted (where ≥2 studies existed), 
seeking to identify potential moderators, methodological bi-
ases, and whether findings extended to clinically relevant sub- 
populations or treatment groups. Subgroup analyses included: 
a) randomization time point (acute vs. maintenance phase); 
b) sponsorship (medication-specific sponsor vs. academia); 
c) study quality (high vs. low Jadad score)18; d) concealment 
(open or single-blinded vs. double-blinded); e) location (inter-
national/USA/Europe/Asia); f ) dosing (fixed vs. flexible), and 
g) first episode vs. chronically ill.
Comprehensive Meta-Analysis, version 3 (Biostat, NJ, USA) 
was used for all two-tailed analyses, with alpha=0.05, without 
adjustments for multiple comparisons. Publication bias was 
assessed with the funnel plot, Egger’s regression test19 and the 
“trim and fill” method20 for the primary outcome, whenever ≥3 
studies were analyzed.
RESULTS
Search and study characteristics
A total of 8,611 references were identified (Figure 1). After 
removing 152 duplicates, we excluded 7,823 of the remaining 
8,459 references based on title/abstract inspection. Of 113 refer-
ences subjected to full-text inspection, 54 articles were dropped 
because of: inappropriate participants (N=17),  review/editorial 
(N=11), no usable data (N=10), inappropriate medication (N=6), 
short-term study (N=4), no/inadequate randomization (N=3), 
and meeting abstracts of already included studies (N=3).
Altogether, we included 63 reports21-83 (59 randomized stud-
ies) with 45,787 participants (median: 255 participants/study, 
range: from 12 to 18,154) (Table 1). The mean age of the popula-
tion was 37.6±7.0 years; 62.1±13.3% were male and 61.1±28.8% 
were white. The mean study duration was 47.4±32.1 weeks 
(range: 24-186).
Forty-six studies included multiple-episode patients, eight 
included exclusively first-episode patients, four included ex-
clusively treatment-resistant patients (all clozapine studies), 
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and one did not report the number of episodes of included pa-
tients79. Thirty-four studies were double-blind, 20 were open-
label, and five had masked raters. Forty studies were sponsored 
by pharmaceutical companies, 18 were publicly funded, and 
funding was uncertain in one study77.
The number of studies with each individual SGA were: 43 for 
olanzapine, 27 for risperidone, 15 for quetiapine, 12 for ziprasi- 
done, 12 for aripiprazole, eight for clozapine, four for amisulpride, 
four for asenapine, two for lurasidone, two for paliperidone, 
one for blonanserin, one for cariprazine, and one for sertindole.
Thirty-nine studies (66.1%) randomized patients in the acute 
phase, eighteen (30.5%) in the maintenance phase, while the ran-
domization time point was uncertain for two studies (3.4%)60,64. Two 
studies33,76 utilized an enriched design, in that patients stabilized 
on drug A were randomized to continued treatment or switch to 
drug B. Two studies70,75 had a “naturalistic” follow-up design, 
in that switches off the originally assigned drugs were allowed.
Eleven studies reported on relapse, and six on remission. 
The definition of relapse varied, with only two studies using 
the same criteria28,47. Three8,31,37 out of six studies reporting on 
remission used Andreasen et al’s criteria84.
Primary outcome measure: all-cause discontinuation
Across 59 studies, the pooled effect sizes of individual SGA 
pairs concerning all-cause discontinuation are shown in Figure 2.
Clozapine had a significantly lower all-cause discontinuation 
as compared with quetiapine (one study, N=64, RR=0.59, 95% 
CI: 0.42-0.83, p=0.002) and risperidone (four studies, N=216, 
RR=0.74, 95% CI: 0.57-0.95, p=0.020, I2=5.1%). Olanzapine had 
a significantly lower all-cause discontinuation as compared with 
paliperidone (one study, N=459, RR=0.64, 95% CI: 0.46-0.90, 
p=0.010), quetiapine (eight studies, N=1,942, RR=0.79, 95% CI: 
0.71-0.89, p<0.001, I2=55.8%), risperidone (16 studies, N=3,131, 
RR=0.88, 95% CI: 0.83-0.93, p<0.001, I2=0.0%), and ziprasidone 
(eight studies, N=20,225, RR=0.82, 95% CI: 0.77-0.87, p<0.001, 
I2=37.0%). Risperidone had a significantly lower all-cause dis-
Records identified 
through database searching 
(N=8,611)
Records excluded because they 
were clearly not relevant or 
duplicates (N=7,975)
Records screened 
(N=636) Records excluded (N=523)
No available data (N=427)
Review (N=96)
Full-text articles assessed 
for eligibility (N=113)
Full-text articles excluded (N=54)
Inappropriate participants (N=17)
No original data (N=11)
No usable data (N=10)
No appropriate drug group (N=6)
Short duration of study (N=4)
No or inadequate randomization (N=3)
Meeting abstract of included articles (N=3)
Studies included in 
meta-analysis (N=59)
Figure 1 PRISMA flow chart
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Figure 2 Results of comparisons of all-cause discontinuation in meta-analysis of second-generation antipsychotics (SGAs). The first drug is the 
one written on the left side of the graph, and the comparator is written in the row of comparison. AMI – amisulpride, APZ – aripiprazole, ASN – 
asenapine, BLO – blonanserin, CAR – cariprazine, CLO – clozapine, LUR – lurasidone, OLZ – olanzapine, PAL – paliperidone, QTP – quetiapine, 
RIS – risperidone, SER – sertindole, ZIP – ziprasidone, M-H RR – Mantel-Haenszel risk ratio.
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continuation as compared with sertindole (one study, N=9,809, 
RR=0.83, 95% CI: 0.80-0.86, p<0.001) and ziprasidone (three 
studies, N=906, RR=0.90, 95% CI: 0.83-0.98, p=0.012, I2=0.0%).
Other significant differences included the following: signifi-
cantly lower all-cause discontinuation for amisulpride vs. que-
tiapine (one study, N=208, RR=0.63, 95% CI: 0.44-0.89, p=0.009); 
significantly higher all-cause discontinuation for aripiprazole vs. 
olanzapine (eight studies, N=2,117, RR=1.17, 95% CI: 1.05-1.30, 
p=0.006, I2=28.8%); significantly higher all-cause discontinua-
tion for lurasidone vs. risperidone (one study, N=629, RR=1.17, 
95% CI: 1.02-1.35, p=0.027); and significantly higher all-cause 
discontinuation for quetiapine vs. ziprasidone (four studies, 
N=1,064, RR=1.12, 95% CI: 1.01-1.25, p=0.031, I2=47.0%).
Secondary outcomes
Across 23 SGA comparisons concerning psychopathology, 
based on 32 studies, the following nine significant differences 
emerged: aripiprazole was superior to quetiapine and ziprasi-
done; clozapine was superior to quetiapine and risperidone; 
lurasidone was superior to quetiapine; olanzapine was supe-
rior to paliperidone and risperidone; and paliperidone was su-
perior to aripiprazole and ziprasidone (Figure 3).
Across 26 comparisons concerning intolerability-related 
discontinuation, based on 50 studies, the following significant 
differences emerged: quetiapine was superior to amisulpride; 
risperidone was superior to clozapine, quetiapine and sertin-
dole; and ziprasidone was superior to clozapine (Figure 4).
Across 20 comparisons concerning inefficacy-related dis-
continuation, based on 47 studies, the following significant 
differences emerged: aripiprazole was superior to quetiapine; 
clozapine was superior to risperidone; lurasidone was superi-
or to quetiapine; and olanzapine was superior to aripiprazole, 
quetiapine and ziprasidone (Figure 5).
Across 11 comparisons concerning relapse, only one signifi-
cant difference emerged: the superiority of olanzapine over ris-
peridone. Across 13 comparisons concerning hospitalization, 
clozapine was superior to olanzapine, and lurasidone and ris-
peridone were superior to quetiapine. Across six comparisons 
concerning remission, lurasidone was superior to quetiapine, 
and quetiapine was superior to risperidone. Across 12 compari-
sons concerning functioning, aripiprazole was superior to que-
tiapine, cariprazine was superior to risperidone, and clozapine 
was superior to olanzapine. Across 11 comparisons concerning 
QOL, there were no significant SGA- pair differences.
Twenty-five comparisons based on 46 studies were meta- 
analyzed for weight gain. Amisulpride, aripiprazole, quetiapine, 
risperidone, paliperidone and ziprasidone were superior to 
olanzapine; amisulpride, cariprazine, lurasidone and ziprasi-
done were superior to risperidone; paliperidone was superior to 
aripiprazole; and ziprasidone was superior to paliperidone and 
quetiapine (Table 2).
Prolactin increase was meta-analyzed in 16 comparisons 
based on 21 studies. Clozapine, lurasidone, olanzapine, que-
tiapine and ziprasidone were superior to risperidone;  ari-
piprazole and quetiapine were superior to olanzapine; olanza-
pine, quetiapine and ziprasidone were superior to amisulpride 
 (Table 2).
Parkinsonism was meta-analyzed in 20 comparisons based 
on 28 studies: olanzapine was superior to risperidone. Dys-
kinesia was meta-analyzed in 11 comparisons based on 13 
studies: ziprasidone was superior to quetiapine. Akathisia was 
meta-analyzed in 11 comparisons based on 9 studies: no sig-
nificant differences emerged. Sedation and/or somnolence 
were meta-analyzed in 17 comparisons based on 27 studies: 
olanzapine and paliperidone were superior to clozapine, and 
risperidone was superior to quetiapine.
Subgroup analyses for primary outcome
In subgroup analyses, the significance of the primary results 
was altered in 49/267 (18.4%) analyses, but most subgroups 
were very small both in number of studies and patients. Com-
parative effectiveness patterns were mostly consistent in high- 
quality studies and double-blind trials.
Regarding industry sponsorship, results showing a spe-
cific drug’s inferiority were neutralized when three of 43 
medication- specific manufacturer-sponsored studies were in-
cluded. In contrast, one outcome showing superiority of olan-
zapine was neutralized when one manufacturer-funded study 
was included.
Regarding blinding, some results changed when we restrict-
ed the analyses to open label or blinded studies. Restricting 
the analyses to only blinded studies, 5/39 results that showed 
statistical significance became non-significant. Restricting the 
analyses to only open label studies, 1/39 non-significant re-
sults became statistically significant.
None of the other potential effect-moderators addressed 
in subgroup analyses revealed a clear pattern of effect. There 
were no subgroup analyses in which the direction of the re-
sults was reversed.
Publication bias
Publication bias for all-cause discontinuation was assessed 
by funnel plot. In nine of eleven comparisons with ≥3 studies, 
the funnel plot was asymmetrical. Subsequently, we applied 
the trim-and-fill method to adjust for potential publication 
bias, and found that the effect sizes were similar after adjust-
ment, and that the significance for RRs did not change, except 
for two comparisons. Quetiapine was not different in observed 
values but became inferior to risperidone in adjusted values 
(original RR=1.07, 95% CI: 0.98-1.18; adjusted RR=1.11, 95% CI: 
1.00-1.24). Quetiapine was significantly inferior in observed 
values, but became not different from ziprasidone in adjusted 
values (original RR=1.12, 95% CI: 1.01-1.25; adjusted RR=1.08, 
95% CI: 0.98-1.19).
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Figure 3 Results of comparisons of psychopathology scores in meta-analysis of second-generation antipsychotics (SGAs). The first drug is the 
one written on the left side of the graph, and the comparator is written in the row of comparison. AMI – amisulpride, APZ – aripiprazole, ASN – 
asenapine, BLO – blonanserin, CAR – cariprazine, CLO – clozapine, LUR – lurasidone, OLZ – olanzapine, PAL – paliperidone, QTP – quetiapine, 
RIS – risperidone, SER – sertindole, ZIP – ziprasidone, SMD – standardized mean difference.
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Figure 4 Results of comparisons of intolerability-related discontinuation in meta-analysis of second-generation antipsychotics (SGAs). The 
first drug is the one written on the left side of the graph, and the comparator is written in the row of comparison. AMI – amisulpride, APZ – ari-
piprazole, ASN – asenapine, BLO – blonanserin, CAR – cariprazine, CLO – clozapine, LUR – lurasidone, OLZ – olanzapine, PAL – paliperidone, 
QTP – quetiapine, RIS – risperidone, SER – sertindole, ZIP – ziprasidone, M-H RR – Mantel-Haenszel risk ratio.
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Figure 5 Results of comparisons of inefficacy-related discontinuation in meta-analysis of second-generation antipsychotics (SGAs). The first 
drug is the one written on the left side of the graph, and the comparator is written in the row of comparison. AMI – amisulpride, APZ – aripipra-
zole, ASN – asenapine, BLO – blonanserin, CAR – cariprazine, CLO – clozapine, LUR – lurasidone, OLZ – olanzapine, PAL – paliperidone, QTP – 
 quetiapine, RIS – risperidone, SER – sertindole, ZIP – ziprasidone, M-H RR – Mantel-Haenszel risk ratio.
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Table 2 Results of  meta-analysis for adverse events
Outcome Comparison n N RR/SMD
95% CI
p I2 (%)Lower limit Upper limit
Akathisia ASN vs. OLZ 1 89 –0.21 –2.00 1.58 0.818 –
CAR vs. RIS 1 460 0.15 –0.18 0.49 0.361 –
CLO vs. OLZ 1 58 0.44 –1.26 2.14 0.614 –
CLO vs. QTP 1 54 –0.97 –2.03 0.08 0.071 –
CLO vs. RIS 1 54 0.30 –1.41 2.00 0.735 –
LUR vs. RIS 1 608 0.13 –0.04 0.30 0.131 –
OLZ vs. QTP 2 201 –0.46 –1.66 0.75 0.459 51.2
OLZ vs. RIS 3 548 –0.08 –0.32 0.17 0.552 17.2
OLZ vs. ZIP 2 725 –0.11 –0.28 0.05 0.184 0.0
QTP vs. RIS 3 1277 0.16 –0.56 0.89 0.657 65.4
QTP vs. ZIP 1 190 0.26 –0.42 0.93 0.458 –
RIS vs. ZIP 1 193 –0.17 –0.97 0.64 0.683 –
Dyskinesia AMI vs. OLZ 1 356 –0.11 –0.32 0.09 0.281 –
AMI vs. RIS 1 310 0.02 –0.21 0.24 0.886 –
ASN vs. OLZ 1 89 –1.46 –3.25 0.33 0.109 –
CLO vs. OLZ 2 88 –0.21 –0.71 0.29 0.416 0.0
CLO vs. QTP 1 44 0.47 –0.76 1.69 0.456 –
CLO vs. RIS 1 45 1.01 –0.61 2.64 0.222 –
OLZ vs. QTP 3 234 –0.35 –0.76 0.07 0.099 0.0
OLZ vs. RIS 7 698 –0.02 –0.19 0.15 0.790 0.0
OLZ vs. ZIP 2 701 –0.03 –0.19 0.13 0.726 0.0
QTP vs. RIS 4 1,301 0.23 –0.28 0.74 0.375 58.8
QTP vs. ZIP 1 165 0.52 0.05 0.99 0.030 –
RIS vs. ZIP 1 156 0.10 –0.44 0.65 0.709 –
Parkinsonism AMI vs. OLZ 2 562 0.26 –0.34 0.86 0.399 77.6
AMI vs. QTP 1 179 0.30 –0.18 0.79 0.219 –
AMI vs. RIS 1 310 0.07 –0.15 0.29 0.539 –
AMI vs. ZIP 1 162 0.03 –0.43 0.50 0.887 –
APZ vs. BLO 1 44 –0.41 –1.74 0.92 0.546 –
APZ vs. OLZ 3 1,483 0.06 –0.27 0.38 0.737 76.5
APZ vs. QTP 2 497 –0.10 –0.45 0.25 0.585 26.6
APZ vs. ZIP 1 124 –0.07 –0.57 0.43 0.776 –
ASN vs. OLZ 2 529 0.08 –0.90 1.06 0.867 16.0
CAR vs. RIS 1 460 –0.23 –0.61 0.15 0.233 –
CLO vs. OLZ 3 201 0.13 –0.18 0.45 0.402 0.0
CLO vs. QTP 1 53 –0.75 –1.90 0.40 0.200 –
CLO vs. RIS 1 54 0.30 –1.41 2.00 0.735 –
LUR vs. RIS 1 621 –0.19 –0.46 0.08 0.169 –
OLZ vs. QTP 5 1,126 –0.08 –0.51 0.36 0.725 51.7
OLZ vs. RIS 9 1,934 –0.28 –0.44 –0.12 0.001 28.3
OLZ vs. ZIP 5 1,808 –0.10 –0.23 0.03 0.129 0.0
QTP vs. RIS 4 1,953 –0.26 –0.60 0.08 0.133 60.5
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Table 2 Results of  meta-analysis for adverse events ( continued )
Outcome Comparison n N RR/SMD
95% CI
p I2 (%)Lower limit Upper limit
QTP vs. ZIP 4 971 –0.19 –0.55 0.18 0.323 44.1
RIS vs. ZIP 2 725 0.40 –0.23 1.03 0.214 66.6
Body weight 
gain
AMI vs. OLZ 3 742 –0.40 –0.54 –0.25 <0.001 0.0
AMI vs. QTP 1 127 –0.06 –0.41 0.29 0.749 –
AMI vs. RIS 1 195 –0.46 –0.83 –0.10 0.013 –
AMI vs. ZIP 1 115 0.36 –0.02 0.74 0.066 –
APZ vs. OLZ 5 1,413 –0.63 –0.81 –0.44 <0.001 31.7
APZ vs. PAL 1 134 0.37 0.03 0.71 0.034 –
APZ vs. QTP 2 501 –0.06 –0.47 0.35 0.774 53.5
APZ vs. ZIP 2 264 0.63 –0.07 1.32 0.077 82.3
APZ vs. BLO 1 44 0.09 –0.50 0.68 0.770 –
ASN vs. OLZ 4 1,447 –0.39 –0.86 0.08 0.107 88.0
CAR vs. RIS 1 431 –0.29 –0.48 –0.10 0.003 –
CLO vs. OLZ 4 1,167 –0.33 –0.80 0.13 0.161 83.0
CLO vs. QTP 1 54 0.02 –0.61 0.64 0.957 –
CLO vs. RIS 3 96 –0.32 –0.78 0.14 0.172 0.0
LUR vs. QTP 1 111 –0.13 –0.54 0.28 0.526 –
LUR vs. RIS 1 621 –0.48 –0.65 –0.31 <0.001 –
OLZ vs. PAL 1 449 0.49 0.31 0.68 <0.001 –
OLZ vs. QTP 8 1,592 0.42 0.21 0.62 <0.001 69.1
OLZ vs. RIS 11 1,646 0.37 0.19 0.55 <0.001 58.5
OLZ vs. ZIP 6 1,509 0.74 0.62 0.85 <0.001 9.6
PAL vs. ZIP 1 132 0.62 0.27 0.97 0.001 –
QTP vs. RIS 8 2,813 0.01 –0.06 0.09 0.701 0.0
QTP vs. ZIP 4 871 0.24 0.10 0.38 0.001 0.0
RIS vs. SER 1 9,809 –0.61 –2.37 1.16 0.501 –
RIS vs. ZIP 3 800 0.22 0.07 0.37 0.003 0.0
Prolactin 
increase
AMI vs. OLZ 1 105 0.63 0.24 1.03 0.002 –
AMI vs. QTP 1 84 0.62 0.18 1.07 0.006 –
AMI vs. ZIP 1 71 1.05 0.53 1.57 <0.001 –
APZ vs. OLZ 4 1,686 –1.09 –1.63 –0.54 <0.001 84.4
APZ vs. QTP 1 382 –0.23 –1.83 1.38 0.783 –
ASN vs. OLZ 1 89 0.07 –0.47 0.61 0.804 –
CLO vs. OLZ 1 55 –0.29 –0.87 0.30 0.333 –
CLO vs. QTP 1 52 0.39 –0.24 1.02 0.229 –
CLO vs. RIS 1 50 –1.62 –2.36 –0.88 <0.001 –
LUR vs. RIS 1 554 –0.56 –0.74 –0.38 <0.001 –
OLZ vs. QTP 6 996 0.13 0.01 0.26 0.040 0.0
OLZ vs. RIS 7 1,225 –1.05 –1.23 –0.87 <0.001 40.7
OLZ vs. ZIP 5 1,510 0.06 –0.16 0.27 0.596 73.1
QTP vs. RIS 8 2,131 –1.24 –1.59 –0.90 <0.001 84.9
QTP vs. ZIP 3 659 0.03 –0.41 0.47 0.890 82.9
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DISCUSSION
In this first comprehensive meta-analysis of comparative ef-
fectiveness, efficacy and tolerability of SGAs in the long-term 
treatment of schizophrenia, including 59 studies and 45,787 
participants, no consistent superiority of any single antipsy-
chotic across multiple outcome domains was observed.
Regarding all-cause discontinuation, clozapine, olanzapine 
and risperidone were superior to several other SGAs, whereas 
quetiapine was inferior to several other SGAs. Regarding psy-
chopathology, clozapine and olanzapine were superior to sev-
eral other SGAs, while again quetiapine as well as ziprasidone 
were inferior to several other SGAs. Regarding functioning, 
QOL and remission, data were sparse.
Regarding intolerability-related discontinuation, risperi-
done was superior and clozapine was inferior to several other 
SGAs. However, it should be kept in mind that discontinuation 
due to adverse events often includes inefficacy-related adverse 
events in modern trials and, therefore, this outcome does not 
purely reflect tolerability.
When broken down into individual adverse events, superi-
ority/inferiority patterns became clearer in some domains. For 
example, olanzapine was associated with more body weight 
gain than all other non-clozapine SGAs, whereas ziprasidone 
was less so than other SGAs; and amisulpride and risperidone 
raised serum prolactin level more than other SGAs. Further-
more, sedation and/or somnolence were more common dur-
ing long-term treatment with clozapine and quetiapine.
We focused on head-to-head comparisons for the current 
meta-analysis. The relative lack of direct head-to-head mainte-
nance comparisons may raise interest in conducting a network 
meta-analysis. However, while such methodology using indi-
rect comparisons can create rankings, the very lack of so many 
comparisons and the heterogeneity of the studies conducted 
in different populations and over several decades are likely to 
introduce relevant biases that are not present in meta-analyses 
of direct head-to-head trials9.
In fact, comparing our results with those from Zhao et al85, 
who conducted a network meta-analysis of relapse prevention 
studies in stable patients with schizophrenia that also included 
first-generation and long-acting injectable antipsychotics, some 
differences emerge. For example, for relapse prevention, the 
only significant result involving an SGA was olanzapine’s supe-
riority over chlorpromazine and haloperidol, whereas we found 
olanzapine to be superior to risperidone (although based on one 
trial only). Furthermore, regarding all-cause discontinuation, we 
Outcome Comparison n N RR/SMD
95% CI
p I2 (%)Lower limit Upper limit
RIS vs. SER 1 9,809 0.00 –0.88 0.88 1.000 –
RIS vs. ZIP 2 596 0.93 0.75 1.10 <0.001 0.0
Sedation and/or 
somnolence
AMI vs. OLZ 1 377 0.99 0.46 2.16 0.989 –
AMI vs. RIS 1 310 0.69 0.29 1.65 0.407 –
APZ vs. BLO 1 44 0.50 0.05 5.12 0.559 –
APZ vs. OLZ 5 1,802 0.64 0.38 1.09 0.099 68.0
APZ vs. QTP 1 119 1.39 0.60 3.24 0.442 –
APZ vs. ZIP 1 124 1.34 0.60 3.00 0.479 –
ASN vs. OLZ 3 1,038 0.89 0.66 1.22 0.477 0.0
CAR vs. RIS 1 460 0.69 0.30 1.59 0.385 –
CLO vs. OLZ 1 956 1.86 1.54 2.23 <0.001 –
CLO vs. RIS 1 14 5.00 0.77 32.57 0.092 –
LUR vs. RIS 1 621 0.76 0.52 1.12 0.166 –
OLZ vs. PAL 1 459 2.85 1.29 6.31 0.010 –
OLZ vs. QTP 4 1,220 0.95 0.83 1.10 0.531 0.0
OLZ vs. RIS 7 1,656 1.14 0.99 1.32 0.064 0.0
OLZ vs. ZIP 2 766 1.78 0.84 3.75 0.130 79.5
QTP vs. RIS 6 3,095 1.46 1.09 1.96 0.010 78.1
QTP vs. ZIP 3 861 1.49 0.89 2.48 0.129 56.7
RIS vs. ZIP 3 906 1.35 0.94 1.95 0.104 41.4
Significant (p<0.05) results are in bold prints. RR – risk ratio, SMD – standardized mean difference, AMI – amisulpride, APZ – aripiprazole, ASN – asenapine, BLO – 
blonanserin, CAR – cariprazine, CLO – clozapine, LUR – lurasidone, OLZ – olanzapine, PAL – paliperidone, QTP – quetiapine, RIS – risperidone, SER – sertindole, 
ZIP – ziprasidone. Effect sizes for sedation and/or somnolence are expressed in RR, others in SMD. SMD <0 and RR<1 indicate superiority of  the first medication.
Table 2 Results of  meta-analysis for adverse events ( continued )
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observed a significant superiority of olanzapine over aripipra-
zole, paliperidone, quetiapine, risperidone and ziprasidone in 
direct comparisons, while Zhao et al, including indirect com-
parisons, found olanzapine only superior to aripiprazole. Thus, 
we believe that restricting the meta- analysis exclusively to ran-
domized head-to-head comparisons yields more precise results.
What are the implications of our findings for the choice of 
SGA in the long-term treatment of schizophrenia? First, we 
must consider the magnitude of the effect sizes for all-cause 
discontinuation. Since these ranged from medium to large, we 
believe that they are clinically meaningful, especially during 
the important maintenance treatment phase2,7,86,87. The re-
sults regarding psychopathology roughly matched the findings 
for all-cause discontinuation, in that clozapine and olanza-
pine were superior to several other SGAs, whereas quetiapine 
seemed inferior, this time together with ziprasidone. However, 
the findings of divergent adverse effect outcomes, with par-
ticular disadvantages for clozapine, olanzapine and risperi-
done, highlight the fact that it is crucial to not view efficacy 
and effectiveness in isolation of tolerability. For example, clo-
zapine and olanzapine are among the medications with some 
of the most problematic adverse effects, including weight gain 
and metabolic abnormalities10,88 as well as, in the case of clo-
zapine, blood dyscrasias89. Given such inconsistent results 
in the different outcome categories, the importance of a bal-
anced medication choice based on each patient’s own situa-
tion should be emphasized.
Regarding the comparative effectiveness of clozapine and 
olanzapine, we found similar results in the maintenance treat-
ment of schizophrenia. Even in studies targeting treatment- 
refractory patients, the effect sizes were similar. Since a network 
meta-analysis of short-term trials in refractory patients did not 
find superiority of clozapine vs. olanzapine, risperidone and 
ziprasidone90, which may have been driven by use of subop-
timal clozapine doses or inclusion of non-refractory patients, 
further high-quality, short- and long-term, head-to-head trials 
of clozapine vs. other SGAs are needed.
Several limitations of this study need to be considered. 
Most comparisons relied on relatively few head-to-head tri-
als. As many as 139 of all 250 comparisons were based on one 
study only, but we only meta-analyzed outcomes for which at 
least two head-to-head trials provided data. The number of 
patients per trial was also often small, and dose equivalencies 
used across studies might not have been balanced or consist-
ent. Furthermore, the limited number of studies reduced the 
power of our exploratory subgroup analyses. Additionally, 
only six and eleven studies reported remission and relapse as 
an outcome, respectively. However, since psychopathology, 
treatment response and functioning can worsen with repeated 
relapse87,91, information on comparative remission and re-
lapse risk with individual antipsychotics is important.
The randomization point in the included studies differed, 
i.e., some studies randomized patients during the acute phase, 
and others during the maintenance phase. Moreover, some 
studies included exclusively treatment-refractory patients, 
whereas some others included exclusively first-episode pa-
tients. Relapse and remission definitions varied across studies. 
Moreover, two of the included studies had an enriched design, 
and two allowed switches after randomization, which could 
have affected the results. Such heterogeneity of the study de-
sign as well as patient populations introduces biases. However, 
we assessed the impact of patient and study design characteris-
tics as potential moderators by conducting subgroup analyses.
Finally, although the effectiveness of long-acting injectable 
antipsychotics (LAIs) in the long-term treatment of schizophre-
nia is clearly important92, we excluded LAI studies, as this as-
pect has already been comprehensively meta-analyzed13,14,93. 
Including LAIs in this meta-analysis, which are not available 
for all SGAs, would have further increased the heterogeneity of 
samples and methods, the complexity of the analyses and the 
interpretation of the results.
In conclusion, results from this meta-analysis suggest that 
there are some significant differences in the effectiveness, ef-
ficacy and tolerability among SGAs in the long-term treatment 
of schizophrenia. Clozapine, olanzapine and risperidone seem 
to be superior to several other SGAs regarding all-cause dis-
continuation, while quetiapine seems to be inferior. Regarding 
psychopathology scores, clozapine and olanzapine seem to be 
superior to several other SGAs, while quetiapine and ziprasi-
done seem to be less effective. Regarding discontinuation due 
to adverse events, only risperidone was superior and clozapine 
was inferior to several other SGAs.
Due to the limited number of head-to-head trials, the com-
parative effectiveness of some SGAs is unclear, and results need 
to be interpreted cautiously whenever they were based on few 
trials. Thus, a sufficiently larger database involving many SGAs 
and including detailed effectiveness and tolerability outcomes 
is desirable to further guide the evidence-based long-term 
treatment of patients with schizophrenia. In particular, identify-
ing predictors of beneficial outcomes with specific antipsychot-
ics would further enhance the ability to personalize treatments.
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